413 related articles for article (PubMed ID: 34947997)
1. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.
Dedic N; Dworak H; Zeni C; Rutigliano G; Howes OD
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947997
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics.
Ågren R; Betari N; Saarinen M; Zeberg H; Svenningsson P; Sahlholm K
Int J Neuropsychopharmacol; 2023 Sep; 26(9):599-606. PubMed ID: 37549917
[TBL] [Abstract][Full Text] [Related]
3. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.
Revel FG; Moreau JL; Pouzet B; Mory R; Bradaia A; Buchy D; Metzler V; Chaboz S; Groebke Zbinden K; Galley G; Norcross RD; Tuerck D; Bruns A; Morairty SR; Kilduff TS; Wallace TL; Risterucci C; Wettstein JG; Hoener MC
Mol Psychiatry; 2013 May; 18(5):543-56. PubMed ID: 22641180
[TBL] [Abstract][Full Text] [Related]
4. A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia.
Kane JM
J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5 Suppl 1):S1-S13. PubMed ID: 36099402
[TBL] [Abstract][Full Text] [Related]
5. TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner.
Yang SM; Ghoshal A; Hubbard JM; Gackière F; Teyssié R; Neale SA; Hopkins SC; Koblan KS; Bristow LJ; Dedic N
Neuropsychopharmacology; 2024 Jun; 49(7):1091-1103. PubMed ID: 38110609
[TBL] [Abstract][Full Text] [Related]
6. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders.
Halff EF; Rutigliano G; Garcia-Hidalgo A; Howes OD
Trends Neurosci; 2023 Jan; 46(1):60-74. PubMed ID: 36369028
[TBL] [Abstract][Full Text] [Related]
7. Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases.
Schwartz MD; Canales JJ; Zucchi R; Espinoza S; Sukhanov I; Gainetdinov RR
Expert Opin Ther Targets; 2018 Jun; 22(6):513-526. PubMed ID: 29798691
[TBL] [Abstract][Full Text] [Related]
8. TAAR1 as an emerging target for the treatment of psychiatric disorders.
Liu J; Wu R; Li JX
Pharmacol Ther; 2024 Jan; 253():108580. PubMed ID: 38142862
[TBL] [Abstract][Full Text] [Related]
9. TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.
Milanović S; Dedic N; Lew R; Burton D; Koblan KS; Camilleri M; Hopkins SC
Diabetes Obes Metab; 2024 Jun; 26(6):2466-2475. PubMed ID: 38533552
[TBL] [Abstract][Full Text] [Related]
10. Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.
Alvarsson A; Zhang X; Stan TL; Schintu N; Kadkhodaei B; Millan MJ; Perlmann T; Svenningsson P
J Neurosci; 2015 Oct; 35(41):14057-69. PubMed ID: 26468205
[TBL] [Abstract][Full Text] [Related]
11. Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia.
Højlund M; Correll CU
Expert Opin Investig Drugs; 2022 Dec; 31(12):1279-1290. PubMed ID: 36533396
[TBL] [Abstract][Full Text] [Related]
12. Binding of SEP-363856 within TAAR1 and the 5HT
Nair PC; Miners JO; McKinnon RA; Langmead CJ; Gregory KJ; Copolov D; Chan SKW; Bastiampillai T
Mol Psychiatry; 2022 Jan; 27(1):88-94. PubMed ID: 34376825
[TBL] [Abstract][Full Text] [Related]
13. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics.
Revel FG; Moreau JL; Gainetdinov RR; Ferragud A; Velázquez-Sánchez C; Sotnikova TD; Morairty SR; Harmeier A; Groebke Zbinden K; Norcross RD; Bradaia A; Kilduff TS; Biemans B; Pouzet B; Caron MG; Canales JJ; Wallace TL; Wettstein JG; Hoener MC
Biol Psychiatry; 2012 Dec; 72(11):934-42. PubMed ID: 22705041
[TBL] [Abstract][Full Text] [Related]
14. In-vivo pharmacology of Trace-Amine Associated Receptor 1.
Lam VM; Espinoza S; Gerasimov AS; Gainetdinov RR; Salahpour A
Eur J Pharmacol; 2015 Sep; 763(Pt B):136-42. PubMed ID: 26093041
[TBL] [Abstract][Full Text] [Related]
15. Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention.
Gomes FV; Grace AA
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922888
[TBL] [Abstract][Full Text] [Related]
16. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity.
Revel FG; Moreau JL; Gainetdinov RR; Bradaia A; Sotnikova TD; Mory R; Durkin S; Zbinden KG; Norcross R; Meyer CA; Metzler V; Chaboz S; Ozmen L; Trube G; Pouzet B; Bettler B; Caron MG; Wettstein JG; Hoener MC
Proc Natl Acad Sci U S A; 2011 May; 108(20):8485-90. PubMed ID: 21525407
[TBL] [Abstract][Full Text] [Related]
17. Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.
Heffernan MLR; Herman LW; Brown S; Jones PG; Shao L; Hewitt MC; Campbell JE; Dedic N; Hopkins SC; Koblan KS; Xie L
ACS Med Chem Lett; 2022 Jan; 13(1):92-98. PubMed ID: 35047111
[TBL] [Abstract][Full Text] [Related]
18. TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding.
Dedic N; Wang L; Hajos-Korcsok E; Hecksher-Sørensen J; Roostalu U; Vickers SP; Wu S; Anacker C; Synan C; Jones PG; Milanovic S; Hopkins SC; Bristow LJ; Koblan KS
Mol Metab; 2024 Feb; 80():101883. PubMed ID: 38237896
[TBL] [Abstract][Full Text] [Related]
19. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.
Achtyes ED; Hopkins SC; Dedic N; Dworak H; Zeni C; Koblan K
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1543-1556. PubMed ID: 37165101
[TBL] [Abstract][Full Text] [Related]
20. The trace amine-associated receptor 1 agonists - non-dopaminergic antipsychotics or covert modulators of D2 receptors?
Reynolds GP
J Psychopharmacol; 2024 Jun; 38(6):503-506. PubMed ID: 38654553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
